A Case of Imatinib Induced Nephrotic Syndrome in a Child with Chronic Myeloid Leukaemia

Mumtahena Mahmuda, T. Chowdhury, M. Quader, A. Karim, Joydip Nandy, Md Naoshad Khan
{"title":"A Case of Imatinib Induced Nephrotic Syndrome in a Child with Chronic Myeloid Leukaemia","authors":"Mumtahena Mahmuda, T. Chowdhury, M. Quader, A. Karim, Joydip Nandy, Md Naoshad Khan","doi":"10.3329/jbcps.v41i2.64507","DOIUrl":null,"url":null,"abstract":"Background:Tyrosin kinase inhibitors (TKI) are used as a targeted therapy for the treatment of chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia. Increasing use of TKI has been associated with hypertension, proteinuria and acute kidney injury. There are only afew reports of adults with TK -inhibitor associated nephrotic syndrome.But TK inhibitor associated Nephrotic syndrome is very rare in paediatric age group.\nCase:A -6- year old boy presented with fever, anaemia, splenomegaly, leucocytosis and finally diagnosed as accelerated phase of chronic myeloid leukaemia (CML) by bone marrow study.He achieved clinical and haematological remission with Imatinib. But developed generalized oedema and was found to have massive proteinuria and microscopic haematuria after three and half months. Renal biopsy revealed focal segmental glomerulosclerosis. Imatinib along with Prednisolone, 60 mg/m2/ day was added to treat nephrotic syndrome. Imatinib discontinued as the patient did not achieve complete remission. After one week of Imatinib withdrawal and five weeks of daily prednisolone the boy attained complete remission of nephrotic syndrome.\nConclusion:Tyrosine Kinase inhibitors are important therapies in paediatric cancer and their use is expanding. Timely recognition of renal adverse effectsfor TK inhibitors can aid in the proper management of cancer patients.\nJ Bangladesh Coll Phys Surg 2023; 41: 170-172","PeriodicalId":89579,"journal":{"name":"Journal of Bangladesh College of Physicians & Surgeons","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bangladesh College of Physicians & Surgeons","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/jbcps.v41i2.64507","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background:Tyrosin kinase inhibitors (TKI) are used as a targeted therapy for the treatment of chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia. Increasing use of TKI has been associated with hypertension, proteinuria and acute kidney injury. There are only afew reports of adults with TK -inhibitor associated nephrotic syndrome.But TK inhibitor associated Nephrotic syndrome is very rare in paediatric age group. Case:A -6- year old boy presented with fever, anaemia, splenomegaly, leucocytosis and finally diagnosed as accelerated phase of chronic myeloid leukaemia (CML) by bone marrow study.He achieved clinical and haematological remission with Imatinib. But developed generalized oedema and was found to have massive proteinuria and microscopic haematuria after three and half months. Renal biopsy revealed focal segmental glomerulosclerosis. Imatinib along with Prednisolone, 60 mg/m2/ day was added to treat nephrotic syndrome. Imatinib discontinued as the patient did not achieve complete remission. After one week of Imatinib withdrawal and five weeks of daily prednisolone the boy attained complete remission of nephrotic syndrome. Conclusion:Tyrosine Kinase inhibitors are important therapies in paediatric cancer and their use is expanding. Timely recognition of renal adverse effectsfor TK inhibitors can aid in the proper management of cancer patients. J Bangladesh Coll Phys Surg 2023; 41: 170-172
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
伊马替尼致儿童慢性髓性白血病肾病综合征1例
背景:酪氨酸激酶抑制剂(TKI)被用作慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病的靶向治疗。TKI的使用增加与高血压、蛋白尿和急性肾损伤有关。只有少数报告成人与TK抑制剂相关的肾病综合征。但TK抑制剂相关性肾病综合征在儿童年龄组非常罕见。病例:1例6岁男童,表现为发热、贫血、脾肿大、白细胞增多,经骨髓检查诊断为慢性髓性白血病(CML)加速期。使用伊马替尼后,患者的临床和血液学均得到缓解。但三个半月后出现全身性水肿,并发现有大量蛋白尿和显微镜下血尿。肾活检显示局灶节段性肾小球硬化。伊马替尼联合强的松龙,60mg /m2/天治疗肾病综合征。由于患者没有完全缓解,伊马替尼停药。在停用伊马替尼一周和每日使用强的松龙五周后,男孩的肾病综合征完全缓解。结论:酪氨酸激酶抑制剂是治疗小儿肿瘤的重要药物,其应用范围正在扩大。及时发现TK抑制剂对肾脏的不良反应有助于癌症患者的正确治疗。[J]孟加拉大学物理外科20123;41: 170 - 172
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinicodemographic Characteristics of COVID-19 Infection Among Patients with Rheumatic Diseases Primary Myelofibrosis in a Young Girl- A Case Report Gastric Xanthoma – A Case Report An Observational Study on Levels of Serum Fibrin Degradation Product (FDP), D-Dimer and Procalcitonin in Burn Sepsis Tolosa Hunt Syndrome- A Case Report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1